Compare Moody's Corporation (MCO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Summit Therapeutics Inc — how do they compare? Moody's Corporation trades at $490.77 (market cap $88.28B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Moody's Corporation is far larger — about 8.4× Summit Therapeutics Inc's market cap, and Moody's Corporation pays a 0.82% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MCO | SMMT | |
|---|---|---|
Market Cap | $88.28B | $10.48B |
Sector | Financials | Health |
52-Week High | $539.61 | $29.32 |
52-Week Low | $412.23 | $13.05 |
Enterprise Value | $94.08B | $9.90B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $490.54, down 3.97% in the last session, with strong fundamentals including 31.69% net income margin and 74.54% ROE. The stock shows bullish technical signals with moving averages supporting upward momentum, while recent earnings consistently beat expectations. Revenue growth has accelerated from $5.5B in 2022 to $7.7B in 2025, with Q2 2026 results expected on July 22, 2026.
MCO presents a compelling investment case with premium valuation metrics (P/E 36.25) justified by exceptional profitability and market dominance. Key risks include valuation sensitivity and dependence on debt issuance cycles. Analyst consensus remains bullish with $558.14 price target, representing 13.8% upside potential from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
